diabetes-congress-cancer-summit-2019-keynote

2 / 3

Volume: 08 Research & Reviews: Journal of Medical & Health Sciences
Page 8
conferenceseries.com
Diabetes Congress & Cancer summit 2019
December 04-05, 2019
December 04-05, 2019 | Tokyo, Japan
Asia Pacific Conference on
Diabetes Oncology
Analysis of the all Russia observational studies: Reduxine® (Sibutramine) safety monitoring in patients
with alimentary obesity and comorbidities
As in many other developed nations, the problem of obesity is acute in Russia, where it’s prevalent in 24.1% of the population
(28 million people). In Russia, Sibutramine (Reduxine) and a combination of Sibutramine and Metformin (ReduxineMet)
are authorized to reduce weight in patients with obesity and type-2 diabetes mellitus or prediabetes. Since the administration
of central-acting drugs as pharmacotherapy of obesity is the most pathogenetically justi ed treatment, the issue of safety of
Sibutramine therapy is very important. In order to implement the principles of active monitoring of the e cacy and safety of
Sibutramine in the current clinical practice and to develop an algorithm of it’s reasonable prescribing the observation studies
“Vesna”, “Primavera” and “Aurora” were conducted in 2011-2017 under the auspices of Endocrinology Research Centre and
the Russian Association of Endocrinologists. e programs were attended by 4,874 doctors of various specialties and 139.305
patients. In “Vesna” study it was shown that Sibutramine therapy is e ective in weight loss, changing eating behavior and
promotes positive changes in LDL, HDL, TG and fasting glucose. In the “Primavera” study the body mass reducing dynamics
during 3, 6, 12 months was 9.5±4.28 kg, 15.0±6.22 kg, 20.0±8.62 kg respectively. Moreover, it was shown that Reduxine therapy
under the supervision of a physician was associated with decreased levels of systolic and diastolic blood pressure and had no
e ect on heart rate. Reduxine® Met in “Aurora” study was being added to the diabetes therapy, that was chosen by the attending
physician, prior to the patient's participation in the program. e average fasting plasma glucose and HbA1c reduction were
2±1.6 mmol/l and 1.2±1.1% respectively. Current studies show, that Sibutramine therapy of obesity according to approved
indications is safe and e ective for long-term treatment in regards to weight loss, regulation of lipemic index, glucose pro le
and quality of life.
Biography
Tatiana Romantsova is currently working as a Professor at Department of Endocrinology in Sechenov University, Moscow. He is the author of 215 scientific articles.
Tatiana Romantsova
I.M. Sechenov First Moscow State Medical University, Russia
Tatiana Romantsova, RRJMHS 2019, ISSN: 2319-9865